Evrofarma SA (EVROF.AT)
EUR 1.63
(0.93%)
EUR 1.63
(0.93%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.31 Million EUR | 83.68% |
| 2022 | 3.95 Million EUR | 76.99% |
| 2021 | 1.63 Million EUR | -17.72% |
| 2020 | 3.42 Million EUR | -34.39% |
| 2019 | 2.52 Million EUR | -6.72% |
| 2018 | 3.49 Million EUR | 0.03% |
| 2017 | 3.43 Million EUR | 12.99% |
| 2016 | 3.9 Million EUR | -28.28% |
| 2015 | 3.84 Million EUR | 43.73% |
| 2014 | 3.43 Million EUR | -18.95% |
| 2013 | 3.21 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 3.38 Million EUR | 0.0% |
| 2023 Q3 | 1.1 Million EUR | -29.09% |
| 2023 FY | - EUR | 83.68% |
| 2023 Q1 | 1.55 Million EUR | 24.77% |
| 2023 Q2 | 1.55 Million EUR | 0.0% |
| 2023 Q4 | 1.1 Million EUR | 0.0% |
| 2022 Q4 | 1.24 Million EUR | 0.0% |
| 2022 Q3 | 1.24 Million EUR | 98.01% |
| 2022 Q1 | 629 Thousand EUR | 1233.33% |
| 2022 FY | - EUR | 76.99% |
| 2022 Q2 | 629 Thousand EUR | 0.0% |
| 2021 FY | - EUR | -17.72% |
| 2021 Q1 | 872.5 Thousand EUR | 31.4% |
| 2021 Q4 | -55.5 Thousand EUR | 0.0% |
| 2021 Q2 | 1.43 Million EUR | 63.9% |
| 2021 Q3 | -55.5 Thousand EUR | -103.88% |
| 2020 Q4 | 664 Thousand EUR | 9.21% |
| 2020 FY | - EUR | -34.39% |
| 2020 Q2 | 1.23 Million EUR | 53.93% |
| 2020 Q1 | 801 Thousand EUR | -26.38% |
| 2020 Q3 | 608 Thousand EUR | -50.69% |
| 2019 Q2 | 1.94 Million EUR | 76.28% |
| 2019 FY | - EUR | -6.72% |
| 2019 Q4 | 1.08 Million EUR | 59.53% |
| 2019 Q3 | 682 Thousand EUR | -64.85% |
| 2019 Q1 | 1.1 Million EUR | 77.5% |
| 2018 Q3 | 620 Thousand EUR | -39.19% |
| 2018 FY | - EUR | 0.03% |
| 2018 Q4 | 620 Thousand EUR | 0.0% |
| 2018 Q2 | 1.01 Million EUR | 0.0% |
| 2018 Q1 | 1.01 Million EUR | 20.37% |
| 2017 Q2 | 806 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 12.99% |
| 2017 Q3 | 847 Thousand EUR | 5.09% |
| 2017 Q4 | 847 Thousand EUR | 0.0% |
| 2017 Q1 | 806 Thousand EUR | 23.24% |
| 2016 FY | - EUR | -28.28% |
| 2016 Q2 | 983 Thousand EUR | 0.0% |
| 2016 Q1 | 983 Thousand EUR | 31.95% |
| 2016 Q4 | 654 Thousand EUR | 0.0% |
| 2016 Q3 | 654 Thousand EUR | -33.47% |
| 2015 Q4 | 745 Thousand EUR | -20.32% |
| 2015 FY | - EUR | 43.73% |
| 2015 Q3 | 935 Thousand EUR | -32.0% |
| 2015 Q2 | 1.37 Million EUR | 9.82% |
| 2015 Q1 | 1.25 Million EUR | 54.38% |
| 2014 FY | - EUR | -18.95% |
| 2014 Q2 | 753 Thousand EUR | -9.28% |
| 2014 Q3 | 988 Thousand EUR | 31.21% |
| 2014 Q4 | 811 Thousand EUR | -17.91% |
| 2014 Q1 | 830 Thousand EUR | 17.9% |
| 2013 Q2 | 961 Thousand EUR | 53.03% |
| 2013 Q3 | 1.14 Million EUR | 18.94% |
| 2013 Q1 | 628 Thousand EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2013 Q4 | 704 Thousand EUR | -38.41% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Flour Mills Kepenos S.A. | 3.64 Million EUR | -45.657% |
| Kri-Kri Milk Industry S.A. | 45.96 Million EUR | 88.442% |
| Loulis Food Ingredients S.A. | 19.85 Million EUR | 73.246% |